GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

Phase 1

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Tafenoquine 150 mg
Drug: Matched placebo 150mg

First Posted Date: 2016-01-18

Last Posted Date: 2018-03-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 486

Registration Number: NCT02658435

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Mepolizumab 100mg SC
Drug: Albuterol/salbutamol MDIs
Drug: Omalizumab

First Posted Date: 2016-01-13

Last Posted Date: 2019-08-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 145

Registration Number: NCT02654145

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.

Not Applicable

Completed

Conditions: Dentin Sensitivity

Interventions: Other: Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)
Other: Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)
Other: Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )

First Posted Date: 2016-01-11

Last Posted Date: 2018-08-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 221

Registration Number: NCT02651467

Locations: 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States

First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Drug: GSK3389404
Drug: Matching Placebo

First Posted Date: 2016-01-06

Last Posted Date: 2019-07-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT02647281

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms

Not Applicable

Completed

Conditions: Xerostomia

Interventions: Other: Biotene mouthwash
Other: Mineral Water

First Posted Date: 2015-12-30

Last Posted Date: 2017-07-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 100

Registration Number: NCT02641912

Locations: 🇺🇸
GSK Investigational Site, Boston, Massachusetts, United States

Safety of 4CMenB Exposure During Pregnancy

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: 4CMenB

First Posted Date: 2015-12-29

Last Posted Date: 2020-09-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2

Registration Number: NCT02640677

Locations: 🇺🇸
GSK Investigational Site, Wilmington, North Carolina, United States

Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine

Phase 1

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
Biological: Investigational MenC-CRM adjuavnted with 100 ug of LHD153R
Biological: Investigational MenC-CRM adjuavnted with 25 ug of LHD153R
Biological: Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R
Biological: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)